Diffuse hemispheric glioma
From Wikipedia the free encyclopedia
| Diffuse hemispheric glioma | |
|---|---|
| Other names | DHG, G34-DHG, DHG-G34 |
| Specialty | Neuro-oncology |
| Causes | Unknown |
| Treatment | Temozolomide |
Diffuse hemispheric glioma, H3G34 mutant (DHG) is a rare, high-grade, infiltrative WHO grade 4 brain tumor most often found in adolescents and young adults.[1][2] The majority are found in the frontal, parietal, and temporal lobes.[3]
Diagnosis[edit]
Most diffuse hemispheric gliomas fell under the classification of glioblastoma historically.[2] However, they have different radiological presentations, including no or faint contrast enhancement.[3] A diagnosis can only be definitively made with genetic testing of the tumor.[4]
Treatment[edit]
Diffuse hemispheric gliomas should be resected, followed by radiation therapy and temozolomide.[5]
Prognosis[edit]
Median time to progression is 10 months. After progression, the median time to death is 5 months. Non-pediatric patients and patients with near-or-gross total resection have increased survival duration.[6]
Pathology[edit]
Diffuse hemispheric gliomas have a distinct mutation in the histone gene H3F3A.[6]
References[edit]
- ^ Picart, Thiébaud; Barritault, Marc; Poncet, Delphine; Berner, Lise-Prune; Izquierdo, Cristina; Tabouret, Emeline; Figarella-Branger, Dominique; Idbaïh, Ahmed; Bielle, Franck; Bourg, Véronique; Vandenbos, Fanny Burel; Moyal, Elizabeth Cohen-Jonathan; Uro-Coste, Emmanelle; Guyotat, Jacques; Honnorat, Jérôme (2021). "Characteristics of diffuse hemispheric gliomas, H3 G34-mutant in adults". Neuro-Oncology Advances. 3 (1): vdab061. doi:10.1093/noajnl/vdab061. ISSN 2632-2498. PMC 8156974. PMID 34056608.
- ^ a b Weller, Michael; van den Bent, Martin; Preusser, Matthias; Le Rhun, Emilie; Tonn, Jörg C.; Minniti, Giuseppe; Bendszus, Martin; Balana, Carmen; Chinot, Olivier; Dirven, Linda; French, Pim; Hegi, Monika E.; Jakola, Asgeir S.; Platten, Michael; Roth, Patrick (March 2021). "EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood". Nature Reviews Clinical Oncology. 18 (3): 170–186. doi:10.1038/s41571-020-00447-z. ISSN 1759-4782. PMC 7904519. PMID 33293629.
- ^ a b Shao, Hanbing; Gong, Jing; Su, Xiaorui; Chen, Ni; Li, Shuang; Yang, Xibiao; Zhang, Simin; Huang, Zhangfeng; Hu, Wei; Gong, Qiyong; Liu, Yaou; Yue, Qiang (2024-03-01). "MRI characteristics of H3 G34-mutant diffuse hemispheric gliomas and possible differentiation from IDH-wild-type glioblastomas in adolescents and young adults". Journal of Neurosurgery. Pediatrics. 33 (3): 236–244. doi:10.3171/2023.10.PEDS23235. ISSN 1933-0715. PMID 38157540.
- ^ Antonelli, Manila; Poliani, Pietro Luigi (December 2022). "Adult type diffuse gliomas in the new 2021 WHO Classification". Pathologica. 114 (6): 397–409. doi:10.32074/1591-951X-823. ISSN 1591-951X. PMC 9763975. PMID 36534419.
- ^ "Diffuse hemispheric glioma, H3 G34 mutant". www.pathologyoutlines.com. Retrieved 2024-04-03.
- ^ a b Kurokawa, Ryo; Baba, Akira; Kurokawa, Mariko; Pinarbasi, Emile S.; Makise, Naohiro; Ota, Yoshiaki; Kim, John; Srinivasan, Ashok; Moritani, Toshio (January 2022). "Neuroimaging features of diffuse hemispheric glioma, H3 G34-mutant: A case series and systematic review". Journal of Neuroimaging. 32 (1): 17–27. doi:10.1111/jon.12939. hdl:2027.42/171545. ISSN 1051-2284. PMID 34632671.